Moderna Announces Positive Phase 3 Data for Combination Vaccine Against Influenza and COVID-19

Moderna, Inc. (NASDAQ:MRNA) has announced that its Phase 3 trial of mRNA-1083, a combination vaccine against influenza and COVID-19, met its primary endpoints. The vaccine generated higher immune responses than the licensed flu and COVID vaccines for adults aged 50 and older.

CEO Stéphane Bancel highlighted the potential of combination vaccines to reduce the burden on health systems and offer more convenient vaccination options. Moderna’s mRNA-1083 includes components of mRNA-1010 for influenza and mRNA-1283 for COVID-19, both showing positive Phase 3 results independently.

The Phase 3 trial, listed under ClinicalTrials.gov Identifier:NCT06097273, involved around 8,000 adults in two age cohorts. mRNA-1083 demonstrated superior immune responses compared to Fluzone HD® and Spikevax® in the 65+ age group and Fluarix® and Spikevax® in the 50-64 age group.

The vaccine showed a favorable safety profile, with most adverse reactions being mild. Moderna plans to present the data at an upcoming medical conference and engage with regulators.